The stock of Bolt Biotherapeutics Inc (BOLT) has seen a -5.05% decrease in the past week, with a -17.54% drop in the past month, and a -25.95% decrease in the past quarter. The volatility ratio for the week is 6.02%, and the volatility levels for the past 30 days are at 7.06% for BOLT. The simple moving average for the past 20 days is -10.22% for BOLT’s stock, with a -32.80% simple moving average for the past 200 days.
Is It Worth Investing in Bolt Biotherapeutics Inc (NASDAQ: BOLT) Right Now?
The 36-month beta value for BOLT is also noteworthy at 0.93. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for BOLT is 25.82M, and at present, short sellers hold a 0.45% of that float. The average trading volume of BOLT on February 05, 2025 was 159.66K shares.
BOLT) stock’s latest price update
The stock of Bolt Biotherapeutics Inc (NASDAQ: BOLT) has decreased by -7.84 when compared to last closing price of 0.51.Despite this, the company has seen a loss of -5.05% in its stock price over the last five trading days. newsfilecorp.com reported 2024-11-11 that Toronto, Ontario–(Newsfile Corp. – Le 11 novembre/November 2024) – Bolt Metals Corp. has announced a two (2) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive one (1) additional share for each share held on such date.
Analysts’ Opinion of BOLT
SVB Leerink, on the other hand, stated in their research note that they expect to see BOLT reach a price target of $36. The rating they have provided for BOLT stocks is “Outperform” according to the report published on March 02nd, 2021.
Stifel gave a rating of “Buy” to BOLT, setting the target price at $40 in the report published on March 02nd of the previous year.
BOLT Trading at -13.92% from the 50-Day Moving Average
After a stumble in the market that brought BOLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.87% of loss for the given period.
Volatility was left at 7.06%, however, over the last 30 days, the volatility rate increased by 6.02%, as shares sank -20.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.24% lower at present.
During the last 5 trading sessions, BOLT fell by -5.05%, which changed the moving average for the period of 200-days by -57.66% in comparison to the 20-day moving average, which settled at $0.5235. In addition, Bolt Biotherapeutics Inc saw -12.17% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BOLT
Current profitability levels for the company are sitting at:
- -7.76 for the present operating margin
- -0.68 for the gross margin
The net margin for Bolt Biotherapeutics Inc stands at -6.66. The total capital return value is set at -0.83. Equity return is now at value -64.99, with -45.72 for asset returns.
Based on Bolt Biotherapeutics Inc (BOLT), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -3.36. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is -52.89.
Currently, EBITDA for the company is -74.34 million with net debt to EBITDA at -0.12. When we switch over and look at the enterprise to sales, we see a ratio of 2.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.16.
Conclusion
In summary, Bolt Biotherapeutics Inc (BOLT) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
